Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News


October 12, 2021 in Portfolio, Poseida Therapeutics, Inc., Rapha Capital Management

Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

New deal with Takeda could mean up to $3.6 billion in milestone payments.
Read More
October 8, 2021 in Asclepix Therapeutics, Inc., Portfolio, Rapha Capital Management

AsclepiX appoints Dr. Amir Shojaei as Chief Scientific Officer and Executive Vice President, Clinical Development

Shojaei brings over two and a half decades of experience in clinical pharmaceutical development BALTIMORE, MD, October 8, 2021 – AsclepiX…
Read More
August 30, 2021 in FIZE Medical Ltd, IMAGIN Medical, Portfolio, Rapha Capital Management

Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.

Rapha Capital BioVentures Fund I, LP (RCBVFI) managed by Rapha Capital leads the financing. Kevin Slawin, M.D., a leading urooncologist…
Read More